Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.
Ficker
D M
DM
Department of Neurology, University of Cincinnati Medical Center, 231 Albert B. Sabin Way, Cincinnati, OH 45267, USA. david.ficker@uc.edu
Privitera
M
M
Krauss
G
G
Kanner
A
A
Moore
J L
JL
Glauser
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D002220:Carbamazepine / Q000008:administration & dosage* / Q000009:adverse effects; D002675:Child, Preschool; D003221:Confusion / Q000139:chemically induced; D003244:Consciousness Disorders / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome
D000927:Anticonvulsants; D002220:Carbamazepine